LPCN - リポシン (Lipocine Inc.)

LPCNのニュース

   Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday''s Mid-Day Session  2023/05/11 17:46:07 Benzinga
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM ) gained 109.8% to $1.06 after reporting a rise in Q1 sales. VCI Global Limited (NASDAQ: VCIG ) shares jumped 63.6% to $5.32. VCI Global reported application for dual listing on Upstream. Polar Power, Inc. (NASDAQ: POLA ) jumped 63.5% to $1.6847 after the company unveiled new line of mobile electric vehicle chargers. Jaguar Health, Inc. (NASDAQ: JAGX ) rose 47.2% to $1.06. Canalevia-CA1, Jaguar Animal Health''s FDA conditionally approved drug for chemotherapy-induced diarrhea in dogs, is now available from Chewy. Minim, Inc. (NASDAQ: MINM ) gained 33% to $6.14. Absolute Software Corporation (NASDAQ: ABST ) shares gained 32.3% to $11.36 after the company announced it will be acquired by Crosspoint Capital Partners for an enterprise value of $870 million. Organogenesis Holdings Inc. (NASDAQ: ORGO ) surged 30% to $2.73 followin strong quarterly sales. Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN ) climbed 29.2% to $36.18 after the company issued strong Q2 guidance.
   Recap: Lipocine Q1 Earnings  2023/05/11 12:25:10 Benzinga
Lipocine (NASDAQ: LPCN ) reported its Q1 earnings results on Thursday, May 11, 2023 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Lipocine missed estimated earnings by 100.0%, reporting an EPS of $-0.04 versus an estimate of $-0.02. Revenue was … Full story available on Benzinga.com
   Lipocine GAAP EPS of -$0.04 misses by $0.01  2023/05/11 10:49:36 Seeking Alpha
Lipocine press release (LPCN): Q1 GAAP EPS of -$0.04 misses by $0.01.
   Lipocine: Q1 Earnings Snapshot  2023/05/11 10:22:31 WTOP
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Lipocine Inc. (LPCN) on Thursday reported a loss of $3.9…
   Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023  2023/05/11 10:00:00 PR Newswire
SALT LAKE CITY, May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first…
   Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket  2023/04/04 12:04:58 Benzinga
Gainers AMC Entertainment Hldg Pref Equity Units (NYSE: APE ) gained 28.4% to $1.90 in pre-market trading. AMC Entertainment Holdings stated it agreed to settle litigation and move forward with converting its preferred stock into common shares. Butterfly Network, Inc. (NASDAQ: BFLY ) jumped 26.2% to $2.36 in pre-market trading after the company received 510(k) clearance for AI-Enable Auto B-Line Counter. Addex Therapeutics Ltd (NASDAQ: ADXN ) gained 15.7% to $1.15 in pre-market trading. Addex published dipraglurant data showing in vivo efficacy on motor and non-motor symptoms of Parkinson''s disease. Meta Materials Inc. (NASDAQ: MMAT ) shares climbed 13.2% to $0.5565 in pre-market trading after jumping 20% on Monday. Meta Materials recently signed a joint development agreement for NPORE battery separator materials with a confidential global Top 10 battery OEM. Clever Leaves Holdings Inc (NASDAQ: CLVR ) climbed 12.3% to $0.40 in pre-market trading. The company recently posted upbeat Q4 results.
   First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154  2023/04/03 12:00:00 Kwhen Finance
   Lipocine Inc. (NASDAQ: LPCN) Could Soar To Much Higher Prices In Coming Months  2023/03/13 13:30:00 Marketing Sentinel
In the last trading session, 1.97 million Lipocine Inc. (NASDAQ:LPCN) shares changed hands as the company’s beta touched 1.00. With the company’s per share price at $0.31 changed hands at -$0.11 or -26.79% during last session, the market valuation stood at $37.14M. LPCN’s last price was a discount, traded about -509.68% off its 52-week high … Lipocine Inc. (NASDAQ: LPCN) Could Soar To Much Higher Prices In Coming Months Read More »
   Lipocine GAAP EPS of -$0.13 in-line, revenue of $0.5M misses by $0.91M  2023/03/10 14:31:06 Seeking Alpha
Lipocine press release (LPCN): FY GAAP EPS of -$0.13 in-line.Revenue of $0.5M (-96.9% Y/Y) misses by $0.91M.As of December 31, 2022, Lipocine had $32.5 million of unrestricted cash,…
   Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock  2023/03/10 13:30:00 Benzinga
SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company''s common stock held of record as of 5:00 p.m. Eastern Time on March 24, 2023 . The shares of Series B Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on March 24, 2023 . The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company''s common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.
   Is Lipocine Inc. (LPCN) a threat to investors?  2022/09/28 12:24:00 US Post News
As of Tuesday, Lipocine Inc.’s (NASDAQ:LPCN) stock closed at $0.39, down from $0.44 the previous day. While Lipocine Inc. has underperformed by -11.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LPCN fell by -64.68%, with highs and lows ranging from $1.89 to $0.43, whereas the […]
   Lipocine Inc. (NASDAQ: LPCN) Is Under Pressure Due To Weak Fundamental Momentum.  2022/09/28 11:30:00 Marketing Sentinel
In the last trading session, 1.1 million Lipocine Inc. (NASDAQ:LPCN) shares changed hands as the company’s beta touched 0.52. With the company’s per share price at $0.39 changed hands at -$0.05 or -11.85% during last session, the market valuation stood at $34.00M. LPCN’s last price was a discount, traded about -384.62% off its 52-week high … Lipocine Inc. (NASDAQ: LPCN) Is Under Pressure Due To Weak Fundamental Momentum. Read More »
   Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%  2022/09/26 13:29:12 Seeking Alpha
Lipocine (LPCN) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system ((CNS)) disorders.LPCN…
   Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference  2022/09/22 20:10:00 PR Newswire
SALT LAKE CITY, Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip''ral platform to augment therapeutics through effective oral delivery by developing differentiated products relative to standard of care,…
   Boom Or Bust: Where Is Lipocine Inc. (NASDAQ: LPCN) Stock Headed Next?  2022/09/10 16:00:00 Marketing Sentinel
Lipocine Inc. (NASDAQ:LPCN)’s traded shares stood at 0.48 million during the last session, with the company’s beta value hitting 0.48. At the close of trading, the stock’s price was $0.51, to imply a decrease of -5.71% or -$0.04 in intraday trading. The LPCN share’s 52-week high remains $1.89, putting it -270.59% down since that peak … Boom Or Bust: Where Is Lipocine Inc. (NASDAQ: LPCN) Stock Headed Next? Read More »

calendar